Enveric Biosciences, Inc. ENVB

Enveric Biosciences secured a new U.S. patent allowance for next-generation, non-hallucinogenic mescaline derivatives in its EVM401 series. Patent strengthens intellectual property protection for core EVM401 drug candidates and supports competitive positioning in development pipeline.

Enveric Biosciences reported new preclinical data supporting the non-hallucinogenic profile of its lead candidate EB-003. Positive preclinical results on lead candidate EB-003 strengthen pipeline prospects and can drive investor sentiment for Enveric Biosciences.

Enveric Biosciences welcomes final FDA guidance for psychedelic drug development. Final FDA guidance directly supports Enveric Biosciences psychedelic drug development and regulatory path.

Enveric Biosciences starts IND-enabling genotoxicity studies on lead neuroplastogen candidate EB-003. Pipeline advancement for lead asset EB-003 supports development progress and may lift sentiment.

Enveric Biosciences reported positive preclinical phototoxicity results for lead neuroplastogen candidate EB-003. Positive preclinical safety data on lead candidate supports pipeline progress but remains early-stage with limited near-term commercial effect.

Enveric Biosciences, Inc. (ENVB) reported financial results and provided a corporate update for the first quarter of 2026. Quarterly financial results and corporate updates moderately affect financial performance and investor sentiment.

Enveric Biosciences, Inc. (ENVB) expands its intellectual property portfolio with a newly issued U.S. patent covering methods of treating psychiatric disorders. New U.S. patent bolsters ENVB's IP in psychiatric treatments, enhancing competitive positioning and long-term market prospects.

Enveric Biosciences, Inc. (ENVB) closed a private placement for up to $13.9 million, priced at-the-market under Nasdaq rules. Raising up to $13.9 million via private placement provides critical funding to advance Enveric Biosciences' pipeline and extend operational runway.

Enveric Biosciences announces up to $13.9 million private placement priced at-the-market under Nasdaq rules, expected to provide gross proceeds for general corporate purposes including clinical development. Private placement raises up to $13.9 million to fund clinical development and operations, significantly extending cash runway and supporting ENVB's biotech pipeline.

Enveric Biosciences, Inc. (ENVB) secures new U.S. patent for EVM301 Series, novel prodrugs of psilocin designed as next-generation treatments for psychiatric disorders including anxiety, depression, and addiction. New patent for EVM301 series strengthens Enveric's IP protection for key psychedelic-derived drug candidates, enhancing competitive positioning and development prospects.

Enveric Biosciences, Inc. (ENVB) reported financial results and provided a corporate update for the fourth quarter and fiscal year ended 2025. Financial results and corporate updates affect key financial performance and investor sentiment but are routine quarterly disclosures.

Enveric Biosciences announces the withdrawal of a petition challenging its patent. Withdrawal eliminates a legal threat to core intellectual property, strengthening competitive positioning and investor sentiment.

Enveric Biosciences, Inc. (ENVB) reported positive receptor engagement assay data for EB-003, demonstrating strong binding affinity to the 5-HT2A receptor and functional agonism, supporting its potential as a next-generation psilocybin derivative for neuropsychiatric disorders. Preclinical receptor engagement data for EB-003 validates target binding and supports pipeline advancement, likely boosting short-term market sentiment without fundamentally altering long-term trajectory.

Enveric Biosciences reports data from EB-003 BRET Receptor Engagement Assay, demonstrating receptor engagement for its psychedelic-based therapeutic candidate. EB-003 assay data release signals preclinical progress in Enveric's pipeline, potentially influencing investor sentiment and development trajectory.

Enveric Biosciences, Inc. has expanded its collaboration with TOTEC Pharma through a trademark license and option agreement. This partnership aims to enhance the development of innovative therapies in the field of psychedelic medicine, leveraging both companies' expertise and resources. The agreement is expected to facilitate the advancement of Enveric's product pipeline and strengthen its market position. The collaboration with TOTEC Pharma represents a significant strategic move that could enhance Enveric's product offerings and market presence.

Enveric Biosciences, Inc. has announced the issuance of a new U.S. patent, which is expected to enhance its intellectual property portfolio. This patent is related to the company's innovative approaches in the field of psychedelic medicine, potentially strengthening its competitive position in the market. The issuance of this patent may facilitate future product development and commercialization efforts. The issuance of a new patent is likely to significantly impact Enveric's future product development and market positioning in the psychedelic medicine sector.

Enveric Biosciences, Inc. announced the issuance of a new patent related to its proprietary technology aimed at enhancing the treatment of mental health disorders. This patent is expected to strengthen the company's intellectual property portfolio and support its ongoing research and development efforts in the psychedelic medicine space. The issuance is seen as a strategic move to bolster Enveric's competitive position in the rapidly evolving market for mental health therapies. The patent issuance is likely to significantly enhance Enveric's competitive position and support future product development in a growing market.

Enveric Biosciences, Inc. has successfully closed the exercise of warrants, resulting in gross proceeds of $3.1 million. This financial move is expected to bolster the company's resources as it continues to focus on developing its psychedelic-based therapies for mental health conditions. The exercise of warrants provides additional funding that may support ongoing projects and operations.

Enveric Biosciences, Inc. has announced the exercise of warrants, resulting in gross proceeds of $3.1 million. This move is expected to enhance the company's financial position and support its ongoing initiatives in the biotechnology sector. The exercise of warrants provides additional funding that may support key operational areas but does not fundamentally alter the company's trajectory.

Enveric Biosciences, Inc. (ENVB) has been highlighted as one of the most active stocks in the market. The company is focused on developing psychedelic-based therapies for mental health conditions. Recent trading activity indicates increased investor interest, potentially driven by broader market trends and developments in the biotech sector. ENVB's stock performance reflects ongoing investor sentiment towards innovative healthcare solutions. Increased trading activity suggests moderate investor interest, which may influence market sentiment and financial performance.

Enveric Biosciences, Inc. has received a Notice of Allowance from the United States Patent and Trademark Office for its EVM301 series of drug candidates. This series is focused on developing treatments for mental health conditions, particularly targeting the endocannabinoid system. The allowance signifies a positive step in the company's efforts to advance its drug development pipeline and enhance its intellectual property portfolio. The Notice of Allowance is a significant regulatory milestone that could enhance Enveric's competitive positioning and market potential in the mental health treatment sector.

Enveric Biosciences, Inc. (ENVB) will present and participate in a panel discussion at the Sachs Associates 9th Annual Neuroscience Innovation Forum during J.P. Morgan Week 2026, highlighting its commitment to advancing neuroscience innovations. Participation in a prominent industry forum may enhance visibility and networking opportunities, potentially influencing future developments.

Enveric Biosciences, Inc. has received its fourth Notice of Allowance from the U.S. Patent and Trademark Office for its EVM401 series of drug candidates, which are aimed at treating various conditions. This notice signifies progress in the company's efforts to secure intellectual property protection for its innovative therapies, potentially enhancing its market position and future product development. The receipt of a fourth Notice of Allowance indicates significant progress in securing intellectual property, which could enhance product development and market positioning.

Enveric Biosciences, Inc. reported its financial and corporate results for the third quarter of 2025, highlighting key metrics and developments in its operations. The company focused on advancements in its product pipeline and strategic initiatives aimed at enhancing its market position. Financial results showed trends that may influence future performance, with management providing insights into upcoming projects and expectations. The financial results and strategic initiatives may moderately influence Enveric's future performance and market positioning.

Enveric Biosciences, Inc. announced a reverse stock split aimed at increasing the per-share price of its common stock. The split will be executed at a ratio of 1-for-10, effective immediately. This move is intended to help the company meet the minimum bid price requirement for continued listing on the Nasdaq. The company believes that the reverse split will enhance its ability to attract institutional investors and improve overall market perception. The reverse stock split may influence market sentiment and investor perception, but its overall effect on the company's trajectory is expected to be limited.

Enveric Biosciences, Inc. has received a new U.S. patent, enhancing its intellectual property portfolio. This patent is related to the company's innovative approaches in the field of psychedelic medicine, which aims to address various mental health conditions. The issuance of this patent is expected to strengthen Enveric's competitive position and support its ongoing research and development efforts. The new patent issuance is likely to significantly enhance Enveric's competitive position and support its strategic initiatives in psychedelic medicine.

Enveric Biosciences, Inc. has filed a patent infringement claim against AbbVie regarding Bretisilocin, alleging that AbbVie’s product violates Enveric's intellectual property rights. This legal action highlights the competitive tensions in the psychedelic therapeutics market, particularly concerning the development of novel treatments for mental health conditions. The outcome of this claim could have significant implications for both companies and their respective product pipelines. The patent infringement claim could significantly impact Enveric's competitive positioning and market dynamics in the psychedelic therapeutics sector.

Enveric Biosciences, Inc. has appointed a prominent intellectual property expert to defend its U.S. patent related to Bretisilocin, a compound recently acquired by AbbVie for $1.2 billion. This strategic move aims to strengthen Enveric's position in the competitive landscape of psychedelic therapeutics. Defending the patent related to a high-value compound like Bretisilocin could significantly impact Enveric's competitive positioning and market sentiment.

Enveric Biosciences, Inc. has engaged the law firm Fish & Richardson to defend a patent related to its collaboration with AbbVie. This move comes amid ongoing legal challenges that could impact the company's strategic interests and partnerships in the biopharmaceutical sector. Defending the patent is likely to influence Enveric's competitive positioning and operational focus, but the overall effect is expected to be somewhat limited.

Enveric Biosciences, Inc. is set to explore opportunities in digital asset treasury management. The company aims to leverage digital assets to enhance its financial strategy and operational efficiency. This initiative aligns with the growing trend of integrating digital currencies and blockchain technology in corporate finance, potentially positioning Enveric favorably in the evolving market landscape. Exploring digital asset treasury opportunities may moderately influence Enveric's financial performance and market positioning.